Trial reportBMC infectious diseases2025
Daily single-strength vs. thrice-weekly double-strength trimethoprim/sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients: a non-inferiority randomized control trial.
Trial report in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk prediction of pneumocystis jirovecii pneumonia in kidney transplant recipients using a clinical nomogram.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumocystis jirovecii pneumonia (PJP) is a significant concern in kidney transplant (KT) recipients, with trimethoprim/sulfamethoxazole (TMP/SMX) as the recommended prophylaxis. However, direct comparisons between daily single-strength (DSS) and thrice-weekly double-strength (TDS) regimens remain limited. This study evaluated the efficacy of DSS versus TDS TMP/SMX for PJP prevention within the first six months post-transplant, along with side effects, renal outcomes, and patient-reported ease of drug consumption.
methodsWe conducted a pilot, single-center, open-label, block-randomized (1:1) non-inferiority trial at Ramathibodi Hospital between December 2022 and December 2023. Adult KT recipients were randomized to receive either TMP/SMX 80/400 mg daily (DSS group) or two SS tablets thrice weekly (TDS group). Patients were followed for six months to assess PJP occurrence, adverse effects, and ease of drug administration.
resultsSixty-five KT recipients were enrolled (DSS: 32, TDS: 33), with a median (IQR) age of 46 (15); 58% were male, 80% received deceased donor kidneys, 17% received anti-thymocyte globulin induction, and 95% were CMV-seropositive. No cases of PJP occurred in either group. The DSS group had a non-significant trend toward lower median (IQR) of white blood cell counts compared to the TDS group [6,235 (3,064) vs.7,052 (3,324) cells/mm3, p = 0.23], with no significant differences in hepatotoxicity or renal dysfunction. Drug convenience was reported in 96% of DSS and 100% of TDS recipients (p = 0.60).
conclusionBoth DSS and TDS TMP/SMX regimens showed comparable safety; however, non-inferiority could not be confirmed due to the absence of PJP in the early post-transplant period. Further studies with larger sample sizes are needed to validate the use of TDS as an alternative prophylactic strategy. (TCTR20220720010, 20 July 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.